

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | FGFR ↓ ↑ | FGFR1 ↓ ↑ | FGFR2 ↓ ↑ | FGFR3 ↓ ↑ | FGFR4 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tyrphostin AG1296 |
+
FGFR (Swiss 3T3), IC50: 12.3 μM |
PDGFR | 99%+ | ||||||||||||||||
| Pazopanib |
+
FGFR, IC50: 140 nM |
99% | |||||||||||||||||
| Erdafitinib | ✔ | RET | 99%+ | ||||||||||||||||
| Gambogenic acid | ✔ | 98+% | |||||||||||||||||
| Sulfatinib |
+++
FGFR1, IC50: 15 nM |
99+% | |||||||||||||||||
| Nintedanib esylate |
+
FGFR1, IC50: 69 nM |
++
FGFR2, IC50: 37 nM |
+
FGFR3, IC50: 108 nM |
98% | |||||||||||||||
| Zoligratinib |
+++
FGFR1, IC50: 9.3 nM |
+++
FGFR2, IC50: 7.6 nM |
++
FGFR3, IC50: 22 nM |
+
FGFR4, IC50: 290 nM |
99%+ | ||||||||||||||
| MK-2461 |
+
FGFR1, IC50: 65 nM |
++
FGFR2, IC50: 39 nM |
++
FGFR3, IC50: 50 nM |
98%+ | |||||||||||||||
| SU 5402 |
++
FGFR1, IC50: 30 nM |
98% | |||||||||||||||||
| Brivanib |
+
FGFR1, IC50: 148 nM |
99%+ | |||||||||||||||||
| Lucitanib |
++
FGFR1, IC50: 17.5 nM |
+
FGFR2, IC50: 82.5 nM |
99%+ | ||||||||||||||||
| Ponatinib |
++++
FGFR1, IC50: 2.2 nM |
98% | |||||||||||||||||
| PD-166866 |
+
FGFR1, IC50: 52.4 nM |
99% | |||||||||||||||||
| Narazaciclib |
++
FGFR1, IC50: 26 nM |
RET | 99%+ | ||||||||||||||||
| Lactate |
+++
FGFR1, IC50: 8 nM |
+++
FGFR3, IC50: 9 nM |
c-Kit,FLT3 | 85% | |||||||||||||||
| Lenvatinib mesylate |
++
FGFR1, IC50: 46 nM |
c-RET | 99% | ||||||||||||||||
| LY2874455 |
++++
FGFR1, IC50: 2.8 nM |
++++
FGFR2, IC50: 2.6 nM |
+++
FGFR3, IC50: 6.4 nM |
+++
FGFR4, IC50: 6 nM |
99%+ | ||||||||||||||
| FIIN-2 |
+++
FGFR1, IC50: 3.09 nM |
+++
FGFR2, IC50: 4.3 nM |
++
FGFR3, IC50: 27 nM |
++
FGFR4, IC50: 45.3 nM |
99% | ||||||||||||||
| FIIN-3 |
+++
FGFR1, IC50: 13.1 nM |
++
FGFR2, IC50: 21 nM |
++
FGFR3, IC50: 31.4 nM |
++
FGFR4, IC50: 35.3 nM |
98% | ||||||||||||||
| Infigratinib |
++++
FGFR1, IC50: 0.9 nM |
++++
FGFR2, IC50: 1.4 nM |
++++
FGFR3 (K650E), IC50: 4.9 nM FGFR3, IC50: 1.0 nM |
+
FGFR4, IC50: 60 nM |
99%+ | ||||||||||||||
| Danusertib |
++
FGFR1, IC50: 47 nM |
RET | 99%+ | ||||||||||||||||
| R1530 |
++
FGFR1, IC50: 28 nM |
98% | |||||||||||||||||
| ENMD-2076 |
+
FGFR1, IC50: 92.7 nM |
+
FGFR2, IC50: 70.8 nM |
RET,FLT3 | 98% | |||||||||||||||
| Dovitinib |
+++
FGFR1, IC50: 8 nM |
+++
FGFR3, IC50: 9 nM |
c-Kit,FLT3 | 99%+ | |||||||||||||||
| Sorafenib |
+
FGFR1, IC50: 580 nM |
99% | |||||||||||||||||
| SSR128129E |
+
FGFR1, IC50: 1.9 μM |
99%+ | |||||||||||||||||
| AZD-4547 |
++++
FGFR1, IC50: 0.2 nM |
++++
FGFR2, IC50: 2.5 nM |
++++
FGFR3, IC50: 1.8 nM |
98% | |||||||||||||||
| Lenvatinib |
++
FGFR1, IC50: 46 nM |
RET | 98% | ||||||||||||||||
| PD173074 |
++
FGFR1, IC50: ~25 nM |
99%+ | |||||||||||||||||
| S49076 |
++
FGFR1, IC50: 18 nM |
+++
FGFR2, IC50: 17 nM |
+++
FGFR3, IC50: 15 nM |
98% | |||||||||||||||
| Futibatinib |
++++
FGFR1, IC50: 1.8 nM |
++++
FGFR2, IC50: 1.4 nM |
++++
FGFR3, IC50: 1.6 nM |
+++
FGFR4, IC50: 3.7 nM |
99%+ | ||||||||||||||
| Ferulic Acid |
+
FGFR1, IC50: 3.78 μM |
+
FGFR2, IC50: 12.5 μM |
98% | ||||||||||||||||
| Nintedanib |
+
FGFR1, IC50: 69 nM |
++
FGFR2, IC50: 37 nM |
+
FGFR3, IC50: 108 nM |
+
FGFR4, IC50: 610 nM |
99+% | ||||||||||||||
| ASP5878 |
++++
FGFR1, IC50: 0.47 nM |
++++
FGFR2, IC50: 0.6 nM |
++++
FGFR3, IC50: 0.74 nM |
+++
FGFR4, IC50: 3.5 nM |
99% | ||||||||||||||
| PRN1371 |
++++
FGFR1, IC50: 0.6 nM |
++++
FGFR2, IC50: 1.3 nM |
+++
FGFR3, IC50: 4.1 nM |
++
FGFR4, IC50: 19.3 nM |
99% | ||||||||||||||
| Derazantinib |
+++
FGFR1, IC50: 4.5 nM |
++++
FGFR2, IC50: 1.8 nM |
+++
FGFR3, IC50: 4.5 nM |
++
FGFR4, IC50: 34 nM |
RET | 99%+ | |||||||||||||
| ODM-203 |
+++
FGFR1, IC50: 11 nM |
+++
FGFR2, IC50: 16 nM |
+++
FGFR3, IC50: 6 nM |
++
FGFR4, IC50: 35 nM |
99%+ | ||||||||||||||
| Pemigatinib |
++++
FGFR1, IC50: 0.4 nM |
++++
FGFR2, IC50: 0.5 nM |
++++
FGFR3, IC50: 1.2 nM |
++
FGFR4, IC50: 30 nM |
99%+ | ||||||||||||||
| SKLB 610 | ✔ | PDGFR | 99%+ | ||||||||||||||||
| Alofanib | ✔ | 99%+ | |||||||||||||||||
| Lirafugratinib | ✔ | 99% | |||||||||||||||||
| Masitinib mesylate | ✔ | FAK | 99%+ | ||||||||||||||||
| BLU9931 |
+
FGFR3, IC50: 150 nM |
+++
FGFR4, IC50: 3 nM |
99%+ | ||||||||||||||||
| BO-264 | ✔ | 99%+ | |||||||||||||||||
| Fisogatinib |
+++
FGFR4, IC50: 5 nM |
99%+ | |||||||||||||||||
| H3B-6527 |
++++
FGFR4, IC50: <1.2 nM |
99%+ | |||||||||||||||||
| Roblitinib |
++++
FGFR4, IC50: 1.9 nM |
99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | FIIN-2 is an irreversible inhibitor of FGFR1-4 with IC50 values of 3.1, 4.3, 27, and 45 nM, respectively. |
| Concentration | Treated Time | Description | References | |
| H1581 cells (FGFR1 V561M mutant) | 23.6 nM | 96 hours | Evaluate the inhibitory effect of FIIN-2 on the proliferation of FGFR1 V561M mutant H1581 cells, showing an EC50 of 23.6 nM | Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):E4869-77. |
| Ba/F3 cells (FGFR2 V564M mutant) | 58 nM | 72 hours | Evaluate the inhibitory effect of FIIN-2 on the proliferation of FGFR2 V564M mutant Ba/F3 cells, showing an EC50 of 58 nM | Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):E4869-77. |
| Ba/F3 cells (FGFR2-dependent) | 1 nM | 72 hours | Evaluate the inhibitory effect of FIIN-2 on the proliferation of FGFR2-dependent Ba/F3 cells, showing an EC50 of 1 nM | Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):E4869-77. |
| Ba/F3 cells (FGFR1-dependent) | 4 nM | 72 hours | Evaluate the inhibitory effect of FIIN-2 on the proliferation of FGFR1-dependent Ba/F3 cells, showing an EC50 of 4 nM | Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):E4869-77. |
| A549/DDP cells | 0-20 μmol/L | 24 hours | FIIN-2 significantly inhibited the proliferation, colony formation, and migration of A549/DDP cells and induced mitochondria-mediated apoptosis. | Cell Death Dis. 2022 Aug 30;13(8):750. |
| A549 cells | 0-20 μmol/L | 24 hours | FIIN-2 significantly inhibited the proliferation, colony formation, and migration of A549 cells and induced mitochondria-mediated apoptosis. | Cell Death Dis. 2022 Aug 30;13(8):750. |
| PF179T CAFs | 0.3 μM–10 μM | 72 hours | Test the growth inhibitory effect of FIIN-2 on PF179T CAFs, results showed significant impact on cell viability at 10 μM concentration | Cancer Med. 2024 Sep;13(18):e70240. |
| CWR-R1 | 0.3 μM–10 μM | 72 hours | Test the growth inhibitory effect of FIIN-2 on CWR-R1 cells, results showed effective growth inhibition at approximately 3 μM concentration | Cancer Med. 2024 Sep;13(18):e70240. |
| VCaP | 0.3 μM–10 μM | 72 hours | Test the growth inhibitory effect of FIIN-2 on VCaP cells, results showed approximately 70% inhibition at 3 μM concentration | Cancer Med. 2024 Sep;13(18):e70240. |
| LNCaP | 0.3 μM–10 μM | 72 hours | Test the growth inhibitory effect of FIIN-2 on LNCaP cells, results showed cytotoxicity at the highest concentration (10 μM) | Cancer Med. 2024 Sep;13(18):e70240. |
| Mouse ovarian cells | 0.25 μM | 5 days | To investigate the inhibitory effect of FIIN-2 on FGFRs and its impact on oocyte numbers. Results showed that inhibition of FGFRs led to a decrease in oocyte numbers and upregulated apoptosis levels in the ovaries. | J Biol Chem. 2023 Jun;299(6):104776. |
| H1581 cells | 1 µM | 6 hours | Evaluate the inhibitory effects of UPR1376 on H1581 cell proliferation | Front Oncol. 2019 Mar 26;9:179. |
| LENTI-4 cells | 1 µM | 1 hour | Evaluate the inhibitory effects of UPR1371-UPR1376 on FGFR1 auto-phosphorylation | Front Oncol. 2019 Mar 26;9:179. |
| Administration | Dosage | Frequency | Description | References | ||
| Nude mice (BALB/c) | A549/DDP xenograft model | Intraperitoneal injection | 20 mg/kg | Twice daily for 28 days | FIIN-2 significantly suppressed tumor growth, and its cytotoxicity was enhanced when combined with the autophagy inhibitor CQ. | Cell Death Dis. 2022 Aug 30;13(8):750. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.58mL 0.32mL 0.16mL |
7.88mL 1.58mL 0.79mL |
15.75mL 3.15mL 1.58mL |
|
| CAS号 | 1633044-56-0 |
| 分子式 | C35H38N8O4 |
| 分子量 | 634.73 |
| SMILES Code | C=CC(NC1=CC=C(CN(C2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC=C2CN5C6=CC(OC)=CC(OC)=C6)C5=O)C=C1)=O |
| MDL No. | MFCD28386553 |
| 别名 | |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, store in freezer, under -20°C |
| 溶解方案 |
DMSO: 30 mg/mL(47.26 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1